Evidence map›Paper›PMID 40371342›Full record

ArticleFrontiers in pharmacology2025

Antibacterial activity of tamoxifen derivatives against methicillin-resistant

Irene Molina Panadero, Javier Falcón Torres, Abdelkrim Hmadcha, Salvatore Princiotto, Luigi Cutarella, Mattia Mori, Sabrina Dallavalle, Michael S Christodoulou, Younes Smani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Irene Molina PanaderoAndalusian Center of Developmental Biology, Consejo Superior de Investigaciones Científicas (CSIC), University of Pablo de Olavide - Seville, Seville, Spain.
Javier Falcón TorresAndalusian Center of Developmental Biology, Consejo Superior de Investigaciones Científicas (CSIC), University of Pablo de Olavide - Seville, Seville, Spain.
Abdelkrim HmadchaDepartment of Molecular Biology and Biochemical Engineering, University of Pablo de Olavide, Seville, Spain.
Salvatore PrinciottoDepartment of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy.
Luigi CutarellaDepartment f Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Mattia MoriDepartment f Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Sabrina DallavalleDepartment of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy.
Michael S ChristodoulouDepartment of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy.
Younes SmaniAndalusian Center of Developmental Biology, Consejo Superior de Investigaciones Científicas (CSIC), University of Pablo de Olavide - Seville, Seville, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of new antimicrobial therapeutic strategies requires urgent attention to prevent the tens of millions of deaths predicted to occur by 2050 as a result of multidrug-resistant (MDR) bacterial infections. This study aimed to discover new tamoxifen derivatives with antimicrobial potential, particularly targeting methicillin-resistant

Indexed as

infectionresistanceStaphylococcus aureustamoxifen derivativestreatment

Identifiers

PMID40371342
PMCPMC12075203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.